CN114773608A - Long-acting hyaluronic acid for treating osteoarthritis and preparation method thereof - Google Patents
Long-acting hyaluronic acid for treating osteoarthritis and preparation method thereof Download PDFInfo
- Publication number
- CN114773608A CN114773608A CN202210439051.9A CN202210439051A CN114773608A CN 114773608 A CN114773608 A CN 114773608A CN 202210439051 A CN202210439051 A CN 202210439051A CN 114773608 A CN114773608 A CN 114773608A
- Authority
- CN
- China
- Prior art keywords
- hyaluronic acid
- acting
- long
- osteoarthritis
- polyethylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 89
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 72
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 72
- 201000008482 osteoarthritis Diseases 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title abstract description 11
- 229920002521 macromolecule Polymers 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 18
- 238000002156 mixing Methods 0.000 claims abstract description 11
- 238000004108 freeze drying Methods 0.000 claims abstract description 9
- 239000002904 solvent Substances 0.000 claims abstract description 9
- 238000006845 Michael addition reaction Methods 0.000 claims abstract description 8
- 125000003396 thiol group Chemical group [H]S* 0.000 claims abstract description 7
- 230000004048 modification Effects 0.000 claims abstract description 6
- 238000012986 modification Methods 0.000 claims abstract description 6
- 238000000502 dialysis Methods 0.000 claims abstract description 5
- 230000008569 process Effects 0.000 claims abstract description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 27
- 239000002202 Polyethylene glycol Substances 0.000 claims description 23
- 229920000642 polymer Polymers 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 5
- 239000002861 polymer material Substances 0.000 claims description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 3
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 2
- 125000004386 diacrylate group Chemical group 0.000 claims description 2
- 229920001002 functional polymer Polymers 0.000 claims description 2
- 229920001427 mPEG Polymers 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 239000000412 dendrimer Substances 0.000 claims 1
- 229920000736 dendritic polymer Polymers 0.000 claims 1
- 238000001727 in vivo Methods 0.000 abstract description 8
- 230000014759 maintenance of location Effects 0.000 abstract description 5
- 239000011259 mixed solution Substances 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 239000007787 solid Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 210000003097 mucus Anatomy 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 210000000845 cartilage Anatomy 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 210000001188 articular cartilage Anatomy 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 210000000629 knee joint Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000001612 chondrocyte Anatomy 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 239000003431 cross linking reagent Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 2
- 108010003272 Hyaluronate lyase Proteins 0.000 description 2
- 102000001974 Hyaluronidases Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 description 2
- 229960002773 hyaluronidase Drugs 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- OQILSTRGJVCFAG-UHFFFAOYSA-N 1-(oxiran-2-ylmethoxy)butan-1-ol Chemical compound CCCC(O)OCC1CO1 OQILSTRGJVCFAG-UHFFFAOYSA-N 0.000 description 1
- OAVCWZUKQIEFGG-UHFFFAOYSA-O 2-(5-methyl-2H-tetrazol-1-ium-1-yl)-1,3-thiazole Chemical compound CC1=NN=N[NH+]1C1=NC=CS1 OAVCWZUKQIEFGG-UHFFFAOYSA-O 0.000 description 1
- SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
Abstract
The invention relates to a long-acting hyaluronic acid for treating osteoarthritis and a preparation method thereof. Specifically, the preparation method comprises the following steps: the modified hyaluronic acid is prepared by blending and modifying the branched macromolecules, the thiolated hyaluronic acid and a solvent, wherein the double bonds in the branched macromolecules and the thiol functional groups on the hyaluronic acid are subjected to Michael addition reaction to obtain a required hyaluronic acid modified product; and removing unreacted branched macromolecules in the mixed solution by a dialysis method, and freeze-drying to obtain a modified hyaluronic acid product. The modified hyaluronic acid product prepared by the invention has good biocompatibility, can be applied to the treatment of osteoarthritis, has the advantages of enzymolysis resistance and capability of realizing long-acting retention in vivo, gel is not formed in the modification process, and the modified hyaluronic acid still keeps good injectability.
Description
Technical Field
The invention belongs to the technical field of hyaluronic acid modification, and particularly relates to long-acting hyaluronic acid for treating osteoarthritis and a preparation method thereof.
Background
Hyaluronic acid is a macromolecular glycosaminoglycan with high viscoelasticity, which is polymerized by taking D-glucuronic acid and N-acetylglucosamine as disaccharide units, and has unique physicochemical properties and wide physiological functions, such as: has the effects of moisturizing, regulating inflammatory reaction, lubricating joints, protecting cartilage, promoting wound healing and the like, and is widely applied to the fields of medical cosmetology, orthopedic treatment, ophthalmic treatment and the like.
When applied in vivo, the hyaluronic acid is rapidly degraded by the action of hyaluronidase, and the retention time is short. Therefore, compared with the hyaluronic acid with small molecular weight, the hyaluronic acid with ultra-high molecular weight (Mw is more than 1000kDa) has unique advantages in application scenes such as minimally invasive fillers and osteoarthritis treatment due to relatively low degradation speed. However, since such high molecular weight hyaluronic acid has a chain-like open structure and is easily degraded by the action of an enzyme, the retention time in the body is still not preferable. To solve this problem, researchers have proposed cross-linking hyaluronic acid molecules to prepare polymer gels to compensate for the too short residence time in vivo. For example, patent CN111440334A discloses a method for preparing an injectable hyaluronic acid-based hydrogel, which forms a hyaluronic acid hydrogel material with controllable mechanical strength and degradation rate through schiff base reaction between modified hyaluronic acid containing amino groups and a cross-linking agent containing a plurality of aldehyde groups. Other commonly used hyaluronic acid cross-linking agents include: BDDE (butanediol glycidyl ether), GMA (glycidyl methacrylate ether), DVS (divinyl sulfone), and the like. However, such hyaluronic acid crosslinking agents tend to be highly toxic and cause a significant decrease in injectability after gelling, limiting their use. Therefore, there is an urgent need to develop a long-acting hyaluronic acid which can increase the in vivo retention time and is advantageous for in vivo application.
Disclosure of Invention
The invention aims to: in view of the problems of the prior art, the present invention aims to provide a long-acting hyaluronic acid for osteoarthritis treatment, which can improve the residence time of hyaluronic acid in vivo and is beneficial to in vivo application; a second object of the present invention is to provide a method for preparing long-acting hyaluronic acid for the treatment of osteoarthritis.
The technical scheme is as follows: the invention provides long-acting hyaluronic acid for treating osteoarthritis, which is prepared by blending and modifying branched macromolecules, thiolated hyaluronic acid and a solvent; the branched macromolecules are polyethylene glycol macromolecules with vinyl end groups, and the solvent is water or PBS buffer solution.
Furthermore, the polyethylene glycol polymer with the vinyl end group is one or more of dendritic polyethylene glycol ((mPEG)4- (PEG)2-MAL), two-Arm polyethylene glycol ((Propargyl-PEG)2-Allyl), three-Arm polyethylene glycol (3Arm (PEG-Allyl)3), four-Arm polyethylene glycol (4Arm (PEG-Allyl)4), six-Arm polyethylene glycol (6Arm-PEG-DA), eight-Arm polyethylene glycol maleimide (8Arm-PEG-MAL) and branched polyethylene glycol diacrylate (HB-PEGDA).
Furthermore, the sulfhydrylation hyaluronic acid is a functional polymer material obtained by grafting sulfhydryl onto a hyaluronic acid chain through a chemical method, the molecular weight is 5-3000 kDa, and the substitution rate of the sulfhydryl is 0.1-2.0 mmol/g.
The preparation method of the long-acting hyaluronic acid for treating osteoarthritis comprises the following specific preparation steps:
(1) adding the branched macromolecules into a solvent, stirring and dissolving to obtain a solution with the concentration range of 0.5-5% (w/v), wherein the preferable concentration is 4%;
(2) adding thiolated hyaluronic acid into a solvent, stirring and dissolving to obtain a solution with the concentration range of 0.1-1% (w/v);
(3) blending and modifying the solutions prepared in the step (1) and the step (2) in proportion to prepare a hyaluronic acid modified product;
(4) dialyzing the hyaluronic acid modified product prepared in the step (3) and separating and purifying unreacted branched macromolecules;
(5) and freeze-drying the separated hyaluronic acid modified product to obtain the long-acting hyaluronic acid for treating osteoarthritis.
Further, the blending modification process in the step (3) is that double bonds in the branched macromolecules and mercapto functional groups on the hyaluronic acid generate Michael addition reaction at normal temperature and are grafted to the hyaluronic acid skeleton.
Further, the pH of the Michael addition reaction is 5 to 10, preferably 6 to 8, and more preferably 7.
Further, the proportion in the step (3) is that the branched macromolecules: the hyaluronic acid is 1: 1-10: 1(w/v), preferably 5: 1.
Further, the cut-off molecular weight of the dialysis bag used for dialysis purification in step (4) is 1000-.
Further, the time period for freeze-drying in step (5) is 1 to 5 days, preferably 2 to 4 days, and more preferably 4 days. .
Has the advantages that: compared with the prior art, the invention has the following advantages:
(1) the steric hindrance of the branched polyethylene glycol macromolecules is utilized to inhibit the contact of hyaluronic acid and enzyme, so that the in-vivo retention time of hyaluronic acid can be obviously prolonged.
(2) The materials of all components of the reaction are nontoxic, have good biocompatibility and small damage to cells.
(3) Compared with the traditional crosslinking method, the strategy for modifying the chain polymer by using the branched polyethylene glycol macromolecules provided by the invention has the advantages that no gel is formed in the modification process, and the modified hyaluronic acid still keeps good injectability.
Drawings
FIG. 1 is a structural diagram of a long-acting hyaluronic acid molecule prepared according to the invention;
FIG. 2 is a structural diagram of an HA-SH molecule prepared in example 1 of the present invention;
FIG. 3 is a nuclear magnetic resonance hydrogen spectrum of the long-acting hyaluronic acid prepared by the invention;
FIG. 4 is a graph of the cell activity of HB-PEGDA prepared in example 1 of the invention;
FIG. 5 is a graph of the cell activity of HA-SH prepared in example 1 of the present invention;
FIG. 6 is a graph of cell activity of long-acting hyaluronic acid prepared in example 2 of the present invention;
FIG. 7 is a diagram of the mechanism of the long-acting hyaluronic acid resistant to enzymatic hydrolysis prepared by the present invention;
FIG. 8 is a graph comparing the degradation of long-acting hyaluronic acid and pure hyaluronic acid prepared according to the invention;
FIG. 9 is a graph of safranin fast green staining of long-acting hyaluronic acid prepared in accordance with the present invention and control treated knee joints;
FIG. 10 is a graph comparing the effect of the long-acting hyaluronic acid prepared according to the invention on the treatment of knee joints with a control group.
Detailed Description
The technical solution of the present invention is further illustrated by the following specific examples.
Example 1
(1) Synthesis of hyperbranched polyethylene glycol (HB-PEGDA) macromolecule: 11.5g of PEGDA monomer (average Mn. about.575 g/mol) was weighed out and added to 50ml of butanone and stirred to dissolve it completely. 0.1839g of Azobisisobutyronitrile (AIBN) and 0.2372g of tetraethylthiuram Disulfide (DS) were then added and the container sealed and the sealing film was wrapped to evacuate the air from the container. And then placing the mixture in an oil bath at 70 ℃, fully and uniformly mixing the mixture through magnetic stirring, stopping the reaction immediately after reacting for 6 hours, introducing air and cooling the mixture to room temperature. The product was purified by pouring a mixed solution of ether and n-hexane (v/v ═ 2:1) into a beaker, and then removing the residual solvent using a rotary evaporator. Adding a certain amount of HB-PEGDA into MEM complete culture medium, preparing a series of HB-PEGDA mixed liquor with concentration gradients of 0, 50, 100, 250, 500 and the like, co-culturing with l-929 cells, and quantitatively characterizing the growth state of the cells by using MTT detection agent after 24h, thereby characterizing the biocompatibility of the synthesized HB-PEGDA.
(2) Preparation of thiolated hyaluronic acid (HA-SH): 100mg of HA was weighed and dissolved in 10ml of MES buffer (pH 4.75, 0.1M), and stirred to dissolve completely; adding 96mg of EDCL, keeping the pH value of the reaction solution at 4.75, and reacting for 5 h; after the reaction, adjusting the pH of the reaction solution to 7.0 by using NaOH; 501mg of DTT were further added and the pH of the reaction solution was adjusted to 8.5 with NaOH; stirring and reacting for 24 hours at normal temperature, and adjusting the pH of the reaction solution to 3.5 by HCl after the reaction; transferring the acidified solution to a dialysis bag, dialyzing with 0.1M NaCl (pH 3.5) solution for 24h, and then dialyzing with deionized water (pH 3.5) for 24 h; and finally, freeze-drying the obtained liquid mixture to obtain the solid HA-SH. And adding a certain amount of solid HA-SH into MEM complete culture medium for full dissolution to prepare a series of HA-SH mixed solutions with concentration gradients, co-culturing with l-929 cells, and quantitatively characterizing the growth state of the cells by using an MTT (methyl thiazolyl tetrazolium) detection agent after 24 hours to characterize the biocompatibility of synthesized HA-SH.
As shown in FIG. 4-FIG. 5, the cell activities were all above 80% in the concentration range of the experiment, which indicates that the synthesized HB-PEGDA HAs good biocompatibility with the modified HA-SH.
Example 2
(1) Synthesis of hyperbranched polyethylene glycol (HB-PEGDA) macromolecule: the synthesis was carried out as described in step (1) of example 1.
(2) Preparation of thiolated hyaluronic acid (HA-SH): the synthesis was performed according to the method described in step (2) of example 1.
(3) Preparing long-acting hyaluronic acid: adding a proper amount of HB-PEGDA into the PBS solution to prepare 4% HB-PEGDA solution, adding a proper amount of solid HA-SH into the PBS solution to prepare 0.5% HA-SH solution, and blending the 4% HB-PEGDA solution and the 0.5% HA-SH solution to make the branched macromolecule: hyaluronic acid 8:1, controlling pH to 7-8, performing Michael addition crosslinking reaction to form polymer mucus, dialyzing with deionized water, and freeze drying for storage.
(4) Adding a certain amount of freeze-dried long-acting hyaluronic acid into MEM complete culture medium, fully dissolving, preparing into HB-PEGDA/HA-SH mixed solution with a series of concentration gradients of 0, 50, 100, 250, 500 and the like, co-culturing with l-929 cells, and quantitatively representing the growth state of the cells by using MTT detection agent after 24h, thereby representing the biocompatibility of the synthesized high polymer material.
As shown in the cell activity chart of FIG. 6, the cell activities were all above 80% in the concentration range of the experiment, which indicates that the finally synthesized HB-PEGDA/HA-SH HAs good biocompatibility.
Example 3
(1) Synthesis of hyperbranched polyethylene glycol (HB-PEGDA) macromolecule: the synthesis was carried out as described in step (1) of example 1.
(2) Preparation of thiolated hyaluronic acid (HA-SH): the synthesis was carried out according to the method described in step (2) of example 1.
(3) Preparing long-acting hyaluronic acid: adding a proper amount of HB-PEGDA into a PBS solution to prepare a 4% HB-PEGDA solution, adding a proper amount of solid HA-SH into the PBS solution to prepare a 0.8% HA-SH solution, and blending the 4% HB-PEGDA solution and the 0.8% HA-SH solution to ensure that the branched macromolecules: controlling the pH value to be 6-7, carrying out Michael addition crosslinking reaction to obtain high-molecular mucus, dialyzing with deionized water, and freeze-drying for storage.
(4) And (3) adding a certain amount of the freeze-dried solid into the PBS solution to prepare mucus with certain viscosity.
(5) 50U/mL hyaluronidase was added to the mucus and the degradation was characterized by changes in viscosity of the mucus over time using a Haake rheometer.
As shown in the degradation-to-degradation curve of FIG. 8, the pure hyaluronic acid is degraded completely in 6 hours, while the modified hyaluronic acid is degraded completely in 48 hours, which shows that the modified hyaluronic acid polymer has better enzymolysis resistance, and the specific enzymolysis resistance mechanism diagram is shown in FIG. 7.
Example 4
(1) Synthesis of hyperbranched polyethylene glycol (HB-PEGDA) macromolecule: the synthesis was carried out as described in step (1) of example 1.
(2) Preparation of thiolated hyaluronic acid (HA-SH): the synthesis was performed according to the method described in step (2) of example 1.
(3) Preparing long-acting hyaluronic acid: adding a proper amount of HB-PEGDA into the PBS solution to prepare 4% HB-PEGDA solution, adding a proper amount of solid HA-SH into the PBS solution to prepare 1% HA-SH solution, and blending 4% HB-PEGDA and 1% HA-SH solution to make the branched macromolecules: controlling the pH value to be 7-8, carrying out Michael addition crosslinking reaction to obtain high-molecular mucus, dialyzing with deionized water, and freeze-drying for storage.
(4) An appropriate amount of the freeze-dried solid was added to physiological saline (0.9% NaCl solution) to prepare a 1.5% HB-PEGDA/HA-SH solution.
The effect of long-acting hyaluronic acid on treatment of osteoarthritis in mice was evaluated by histological evaluation. At 2 weeks after DMM surgery, the knee joint of the mice was injected with a commercial osteoarthritis Alzhen injection (clinical HA), a synthetic HB-PEGDA/HA-SH solution (long-acting HA), and physiological saline, respectively. The long-acting HA is injected once, and the clinical HA and the normal saline are injected once a week for four times. After 4 weeks of intra-articular injection, the knee joints were harvested for histological examination, and fig. 9 shows representative histological images of articular cartilage, and safranin fast green staining showed severe cartilage damage, rough and uneven articular cartilage surface, cartilage layer defect, cartilage four-layer disorder (cartilage surface layer, transitional layer, radiation layer, calcified layer), significantly reduced chondrocyte number, significant fibrosis and hyperplasia, multiple tide lines and uneven staining in untreated mice. However, after clinical HA and long-acting HA treatment, the shape and the structure of the articular cartilage are greatly improved, the four-layer structure is clear and distinguishable, no crack exists, the arrangement of chondrocytes is tight, the tide line is complete, the cell nucleus is clear, the staining is uniform, and the treatment effects are not observed when normal saline is injected. Meanwhile, the extent of degeneration of the articular cartilage surface of osteoarthritic mice was evaluated and graded using the OARSI scoring system. The standard score is based on the evaluation of four parameters: cartilage structure, chondrocytes, safranin O staining and tide lines were scored by three independent observers, taking the mean of the three scores as the final score. As shown in fig. 10, independent sample assay analysis was used within the group; n-3, p <0.05, p <0.01, p <0.001, ns: the OARSI score result shows that the mouse score of the operation group is 8.7, however, the osteoarthritis mouse injected with long-acting HA is greatly reduced to only 3.7, and HAs no significant difference with clinical HA, thereby showing that the synthetic natural polymer material HAs the potential in treating osteoarthritis.
The above embodiments are merely illustrative of the technical ideas and features of the present invention, and the purpose thereof is to enable those skilled in the art to understand the contents of the present invention and implement the present invention, and not to limit the protection scope of the present invention. All equivalent changes and modifications made according to the spirit of the present invention should be covered within the protection scope of the present invention.
Claims (10)
1. The long-acting hyaluronic acid for treating osteoarthritis is characterized by being prepared by blending and modifying branched macromolecules, thiolated hyaluronic acid and a solvent; the branched macromolecule is a polyethylene glycol macromolecule with a vinyl end group.
2. The long-acting hyaluronic acid for osteoarthritis treatment according to claim 1, wherein the vinyl-terminated polyethylene glycol polymer is one or more of dendrimer ((mPEG)4- (PEG)2-MAL), two-armed polyethylene glycol ((Propargyl-PEG)2-Allyl), three-armed polyethylene glycol (3Arm (PEG-Allyl)3), four-armed polyethylene glycol (4Arm (PEG-Allyl)4), six-armed polyethylene glycol (6Arm-PEG-DA), eight-armed polyethylene glycol maleimide (8Arm-PEG-MAL), and branched polyethylene glycol diacrylate (HB-PEGDA).
3. The long-acting hyaluronic acid for osteoarthritis treatment according to claim 1, wherein the thiolated hyaluronic acid is a functional polymer material obtained by chemically grafting a thiol group onto a hyaluronic acid chain, and has a molecular weight of 5-3000 kDa and a thiol group substitution rate of 0.1-2.0 mmol/g.
4. The long-acting hyaluronic acid for the treatment of osteoarthritis according to claim 1, wherein the solvent is water or PBS buffer.
5. The method of preparing long-acting hyaluronic acid for the treatment of osteoarthritis according to any of claims 1-4, comprising the steps of:
(1) adding the branched macromolecules into a solvent, stirring and dissolving to obtain a solution with the concentration range of 0.4-4% (w/v);
(2) adding the thiolated hyaluronic acid into a solvent, stirring and dissolving to obtain a solution with the concentration range of 0.1-1% (w/v);
(3) blending and modifying the solutions prepared in the steps (1) and (2) in proportion to prepare a hyaluronic acid modified product;
(4) dialyzing the hyaluronic acid modified product prepared in the step (3) and separating and purifying unreacted branched macromolecules;
(5) and freeze-drying the separated hyaluronic acid modified product to obtain the long-acting hyaluronic acid for treating osteoarthritis.
6. The method of claim 5, wherein the blending modification process comprises grafting double bonds in the branched macromolecules and thiol functional groups on the hyaluronic acid onto the hyaluronic acid skeleton by Michael addition reaction at room temperature.
7. The method of producing long-acting hyaluronic acid for the treatment of osteoarthritis according to claim 6, wherein the pH of the Michael addition reaction is 5-10.
8. The method for preparing long-acting hyaluronic acid for osteoarthritis treatment according to claim 5, wherein the ratio in step (3) is branched macromolecules: hyaluronic acid is 1: 1-10: 1 (w/v).
9. The method for preparing long-acting hyaluronic acid for the treatment of osteoarthritis as claimed in claim 5, wherein the molecular weight cut-off of the dialysis bag used in the step (4) is 1000-100000 Da.
10. The method of preparing long-acting hyaluronic acid for the treatment of osteoarthritis according to claim 5, wherein the time for lyophilization in step (5) is 1-5 days.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022104025233 | 2022-04-18 | ||
| CN202210402523 | 2022-04-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114773608A true CN114773608A (en) | 2022-07-22 |
Family
ID=82432273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210439051.9A Pending CN114773608A (en) | 2022-04-18 | 2022-04-25 | Long-acting hyaluronic acid for treating osteoarthritis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114773608A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150266986A1 (en) * | 2014-03-20 | 2015-09-24 | National University Of Ireland, Galway | Multifunctional Hyperbranched Polymers |
| CN112480417A (en) * | 2019-09-11 | 2021-03-12 | 天津大学 | Natural polymer-based injectable hydrogel and preparation method thereof |
| CN113058511A (en) * | 2021-04-23 | 2021-07-02 | 南京工业大学 | Preparation method of oligonucleotide carrier microsphere |
-
2022
- 2022-04-25 CN CN202210439051.9A patent/CN114773608A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150266986A1 (en) * | 2014-03-20 | 2015-09-24 | National University Of Ireland, Galway | Multifunctional Hyperbranched Polymers |
| CN112480417A (en) * | 2019-09-11 | 2021-03-12 | 天津大学 | Natural polymer-based injectable hydrogel and preparation method thereof |
| CN113058511A (en) * | 2021-04-23 | 2021-07-02 | 南京工业大学 | Preparation method of oligonucleotide carrier microsphere |
Non-Patent Citations (2)
| Title |
|---|
| XIAOLIN LI ET AL: ""Cartilage-Derived Progenitor Cell-Laden Injectable Hydrogel-An Approach for Cartilage Tissue Regeneration"", 《ACS APPL. BIO MATER.》 * |
| 梁嘉碧等: ""原位交联透明质酸水凝胶的制备及体外生物 位交联透明质酸水凝胶的制备及体外生物相容性研究"", 《中国修复重建外科杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110128682B (en) | Sulfhydryl-aldehyde crosslinking hydrogel material and preparation method and application thereof | |
| Kumar et al. | Application of xanthan gum as polysaccharide in tissue engineering: A review | |
| Liu et al. | Thermosensitive injectable in-situ forming carboxymethyl chitin hydrogel for three-dimensional cell culture | |
| Bacelar et al. | Recent progress in gellan gum hydrogels provided by functionalization strategies | |
| Zhang et al. | Cytocompatible and non-fouling zwitterionic hyaluronic acid-based hydrogels using thiol-ene “click” chemistry for cell encapsulation | |
| Zhang et al. | Preparation and characterization of carboxymethyl chitosan/collagen peptide/oxidized konjac composite hydrogel | |
| Zhang et al. | Cytocompatible injectable carboxymethyl chitosan/N-isopropylacrylamide hydrogels for localized drug delivery | |
| Tan et al. | Thermosensitive injectable hyaluronic acid hydrogel for adipose tissue engineering | |
| Fan et al. | Cytocompatible in situ forming chitosan/hyaluronan hydrogels via a metal-free click chemistry for soft tissue engineering | |
| Yan et al. | Injectable in situ self-cross-linking hydrogels based on poly (L-glutamic acid) and alginate for cartilage tissue engineering | |
| JP6106686B2 (en) | Water-insoluble gel composition and method for producing the same | |
| Chen et al. | Enzyme-catalyzed gel formation of gelatin and chitosan: potential for in situ applications | |
| KR100674177B1 (en) | Cross-linked hyaluronic acids and medical uses thereof | |
| US8859523B2 (en) | Crosslinked compounds and methods of making and using thereof | |
| RU2523182C2 (en) | Method of obtaining functionalised derivatives of hyaluronic acid and formation of their hydrogels | |
| Chen et al. | Preparation and evaluation of thermo-reversible copolymer hydrogels containing chitosan and hyaluronic acid as injectable cell carriers | |
| WO2009006780A1 (en) | A method for the formation of a rapid-gelling biocompatible hydrogel and the preparation of a spraying agent | |
| Komoto et al. | Preparation of polyelectrolyte complex gel of sodium alginate with chitosan using basic solution of chitosan | |
| EP2038308A2 (en) | Thiolated macromolecules and methods of making and using thereof | |
| CN113454166A (en) | Hydrogel compositions based on polysaccharides and zwitterionic polymers and methods of use thereof | |
| Li et al. | Synthesis of thiol-terminated PEG-functionalized POSS cross-linkers and fabrication of high-strength and hydrolytic degradable hybrid hydrogels in aqueous phase | |
| EP0977780B1 (en) | Hetero-polysaccharide conjugates, s-inp polysaccharide gels and methods of making and using the same | |
| CN112812329B (en) | Hydrogel of sulfhydryl modified high molecular compound, preparation method and application thereof | |
| Ma et al. | Injectable hyaluronic acid/poly (γ-glutamic acid) hydrogel with step-by-step tunable properties for soft tissue engineering | |
| Zafar et al. | Role of crosslinkers for synthesizing biocompatible, biodegradable and mechanically strong hydrogels with desired release profile |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |